Northland Biotech Actively Developing Commercialization Strategy for NL003 Gene Therapy

Northland recently stated in an investor research meeting that the company is actively conducting commercialization strategy research for the NL003 project. It has currently partnered with Ims Market Research Consulting (Shanghai) Co., Ltd., a global healthcare data and clinical research services company, to carry out product pricing and comprehensive market research. At the same time, regarding the sales and cooperative promotion of NL003, the company is in communication with relevant enterprises. Based on the research results as well as various market factors such as the characteristics and value positioning of the project, market regions, medical insurance pathways, and sales strategies, the company will consider whether to build its own team or seek third-party cooperation. The company aims to plan and formulate the commercialization strategy for NL003 in advance, laying a solid foundation for its smooth entry into the market.